Biogen Idec, Swedish Orphan Biovitrum present outcomes from rFIXFc Phase 1/2a research in hemophilia B Biogen Idec and Swedish Orphan Biovitrum Abdominal today announced outcomes from a Phase 1/2a open-label, dose-escalation, protection and pharmacokinetic research of the businesses’ long-lasting, fully-recombinant element IX Fc fusion proteins in hemophilia B sufferers. The data, that have been presented at the Globe Federation of Hemophilia Congress in Buenos Aires, Argentina, on 11 July, 2010, demonstrated that rFIXFc was well tolerated and demonstrated an around three-fold upsurge in half-life compared to historic data for existing therapies.D ., Medical Director of the Indiana Thrombosis and Hemophilia Middle.

Other entries from category "treatments":

Random entries